Alpha Cognition Inc. Advances Alzheimer's Treatment with ZUNVEYL® in Texas and Beyond

Alpha Cognition Inc. (NASDAQ: ACOG) has reported significant progress in the commercialization of ZUNVEYL®, its innovative treatment for Alzheimer's disease, during the second quarter of 2025. The drug has seen meaningful early adoption in the U.S. long-term care (LTC) market, with orders from over 300 facilities across priority regions. A notable 65% of these facilities have placed repeat orders, underscoring the treatment's strong clinical confidence and operational fit. The engagement of Alpha Cognition's sales team with more than 3,700 healthcare professionals has led to both new and repeat prescriptions, with clinicians praising ZUNVEYL's cognitive and behavioral benefits alongside its favorable tolerability profile.

A pivotal achievement for Alpha Cognition was securing its first national Medicare Part D contract, which notably requires no prior authorization. This development significantly enhances patient access to ZUNVEYL ahead of schedule, addressing a critical barrier for a substantial portion of the Alzheimer's patient population. Alzheimer's disease affects approximately 7 million Americans, with over 11 million prescriptions written annually. However, more than half of patients discontinue treatment within a year due to side effects, highlighting the importance of treatments like ZUNVEYL that offer a favorable tolerability profile.

Financially, ZUNVEYL generated $1.6 million in net product sales in the second quarter of 2025, contributing to a year-to-date net product revenue of approximately $2.0 million. Additionally, licensing revenue from the Centers for Medicare & Medicaid Services (CMS) partnership added $0.08 million. The company's research and development (R&D) expenses decreased to $0.32 million from $0.97 million a year ago, while selling, general, and administrative (SG&A) expenses rose to $6.54 million from $1.43 million, reflecting the company's investments in commercialization efforts. Despite a net operating loss of $5.74 million and a widened net loss to $10.49 million due to a non-cash loss on warrant liabilities, Alpha Cognition concluded the quarter with $39.4 million in cash and equivalents, providing an estimated two years of operational runway at current expenditure rates.

Looking forward, Alpha Cognition is dedicated to supporting LTC homes and pharmacies in navigating the regulatory landscape and aims to secure another national contract before the end of the year. The company has also made strides in its research efforts, completing a Department of Defense-funded pre-clinical study of ALPHA-1062 in a repetitive mild traumatic brain injury model. The results demonstrated reductions in neuroinflammation and neuropathology. Additionally, work on a sublingual ALPHA-1062 formulation for patients with dysphagia or aphasia is progressing as planned, with completion expected in the first quarter of 2026, followed by a comparative pharmacokinetic (PK) study and Investigational New Drug (IND) submission in the first half of 2026.

Stonegate Capital Partners has updated its coverage on Alpha Cognition, employing a Discounted Cash Flow (DCF) Model to guide its valuation. This model produces a valuation range of $32.69 to $43.65, with a mid-point of $37.49. For further details on Alpha Cognition's advancements and financial performance, visit https://www.alphacognition.com.